^
Association details:
| Biomarker: | EGFR mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Rui Bi Da (rezivertinib) (EGFR antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study
Published date:
01/08/2023
Excerpt:
Rezivertinib (BPI-7711) showed promising efficacy and a favorable safety profile for the treatment among the locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation in the first-line setting.
DOI:
https://doi.org/10.1186/s12916-022-02692-8
Trial ID:
Source:
Title:
981P - A phase IIa study to evaluate safety and efficacy of rezivertinib (BPI-7711) in locally advanced or metastatic/recurrent treatment-naïve NSCLC patients with EGFR mutation
Published date:
09/05/2022
Excerpt:
This study aimed to evaluate the efficacy and safety of rezivertinib in treatment-naïve patients with locally advanced or metastatic/recurrent EGFR mutated non-small cell lung cancer (NSCLC)....Rezivertinib showed promising efficacy and favorable safety for locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation at first-line setting.
Trial ID:
